Safety Warning: LL37 Peptide as Autoantigen
Dr. Yurth advises against using LL-37 peptide for reactive arthritis unless the patient's Vitamin D levels are optimized to 80-110 ng/mL. She warns that LL-37 can act as an autoantigen, potentially exacerbating autoimmune responses if not carefully managed.
Comprehensive HSV Management Outcome Data
Speaker cites a 2022 study by Prusty in Viruses examining comprehensive HSV management combining immune training peptides, antiviral compounds, nerve repair peptides, and nutrient restoration. Results showed 76% reduction in outbreak frequency, 89% reduction in outbreak severity, 84% reduction in neuropathic pain, with sustained improvement at 12-month follow-up. [Audit 2026-10-04: the cited study could not be located in the literature. Tier lowered from human-obs to expert-opinion; treat the figures as the speaker's claim.]
IM Route Preferred for Faster Peptide Absorption in Acute Viral Cases
Speaker specifically chose intramuscular (IM) administration for Thymosin Alpha-1, LL-37, and BPC-157 rather than subcutaneous, stating the rationale was faster absorption needed in active viral suppression cases. KPV was the exception, administered subcutaneously.
Complete HSV Peptide + Supplement Stack Protocol
Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.